QJM Advance Access published online on June 10, 2008
QJM, doi:10.1093/qjmed/hcn066
Adipokines—targeting a root cause of cardiometabolic risk
From the Thames House, Barnet General Hospital, Barnet & Chase Farm NHS Trust, Wellhouse Lane, Barnet EN5 3DJ, England, UK
Address correspondence to Ameet Bakhai, Consultant Cardiologist, 3rd Floor, Thames House, Barnet General Hospital, Barnet & Chase Farm NHS Trust, Wellhouse Lane, Barnet EN5 3DJ, England, UK. email: Ameet.Bakhai{at}bcf.nhs.uk
Received 18 February 2008 and in revised form 24 April 2008
| Abstract |
|---|
Obesity often co-presents with other cardiometabolic risk factors such as dyslipidaemia, insulin resistance and hypertension. Less well appreciated is that dysregulation of adipokine production by excess adipose tissue also promotes a state of low-level systemic chronic inflammation and a prothrombotic state, implicated in the development of both atherosclerosis and subsequently cardiovascular events. Lifestyle modification and pharmacological therapy can reduce cardiometabolic risk, a benefit that may be partly due to their effects on adipokine levels.